Transarterial radioembolization for management of hepatocellular carcinoma
Transarterial radioembolization (TARE) with Yttrium-90 (Y90) is a growing area of study due
to its benefits in early-, intermediate-, and late-stage hepatocellular carcinoma. Treatment …
to its benefits in early-, intermediate-, and late-stage hepatocellular carcinoma. Treatment …
局部治疗联合系统治疗在肝细胞癌转化治疗中的价值
朱超凡， 王晓东 - 临床肝胆病杂志, 2024 - lcgdbzz.org
肝细胞癌是临床中最常见的恶性肿瘤之一. 由于早期缺乏典型的临床表现,
我国大多数患者确诊时已达中晚期, 错失手术切除机会, 预后较差. 因此通过相关治疗手段将不可 …
我国大多数患者确诊时已达中晚期, 错失手术切除机会, 预后较差. 因此通过相关治疗手段将不可 …
Advancing Radioembolization Through Personalized Dosimetry
S Young, D Goldberg… - Advances in …, 2024 - advancesinclinicalradiology.com
Transarterial radioembolization (TARE) has been shown to be an effective treatment
modality for a number of different primary and secondary cancers of the liver [1–6]. However …
modality for a number of different primary and secondary cancers of the liver [1–6]. However …
Value of local treatment combined with systemic therapy in conversion therapy for hepatocellular carcinoma
ZHU Chaofan - 临床肝胆病杂志, 2024 - lcgdbzz.org
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in clinical
practice. Due to the lack of typical clinical manifestations in the early stage, most patients in …
practice. Due to the lack of typical clinical manifestations in the early stage, most patients in …